Indoco Remedies is currently trading at Rs. 290.65, up by 14.05 points or 5.08% from its previous closing of Rs. 276.60 on the BSE.
The scrip opened at Rs. 276.75 and has touched a high and low of Rs. 294.75 and Rs. 276.75 respectively. So far 9923 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 335.55 on 19-Jan-2021 and a 52 week low of Rs. 145.50 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 297.90 and Rs. 275.30 respectively. The current market cap of the company is Rs. 2658.08 crore.
The promoters holding in the company stood at 58.69 % while Institutions and Non-Institutions held 19.99 % and 21.32 % respectively.
Indoco Remedies has launched Brinzolamide Ophthalmic Suspension 1% in the United States, the first generic version of AZOPT by Teva Pharmaceuticals. The product is developed and manufactured by Indoco Remedies for TEVA at its facility in Goa.
The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic Suspension 1%, is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide Ophthalmic Suspension 1% works by decreasing the amount of fluid within the eye.The US market size of this product is $184 million, according to IQVIA data as of December, 2020.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: